Načítá se...
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
BACKGROUND: The 2019 novel coronavirus disease (COVID-19) causes for unresolved reasons acute respiratory distress syndrome in vulnerable individuals. There is a need to identify key pathogenic molecules in COVID-19-associated inflammation attainable to target with existing therapeutic compounds. Th...
Uloženo v:
| Vydáno v: | Mol Med |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7203545/ https://ncbi.nlm.nih.gov/pubmed/32380958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10020-020-00172-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|